[ @entity2592 in high doses in refractory acute XXXX . Apropos of 17 cases].

@entity1 @entity632 @entity2194 @entity137 @entity2800 @entity3052 @entity2592 @entity204
A total of 17 @entity1 , 6 female and 11 male (age range 13 to 56 years), received high dose @entity2592 for treatment of refractory acute @entity2800 . @entity2592 was given at 3 g/m2 twice daily for 6 days as a 1 infusion. 1 @entity1 (with induced @entity3052 ) was treated directly, two after failure of a chemotherapy schedule containing the usual dose @entity2592 , 12 for first relapse and 2 for subsequent relapse. Maximum follow up is 16 months. Beside hematological @entity137 , systemic tolerance was good with no neurological of cutaneous effects. Despite preventive corticoid eyewash, @entity2194 occurred in 6 cases, mild and resolvable in 5 of them. The immediate results were as follows: 3 deaths during induction (18%); 6 failures (35%); 8 complete remissions (CR) (47%). After primary chemo-resistance (two cases) failure was always noted. In 3 cases, after less than 12 infusions had been given, 2 failures and 1 very short CR were noted. In 2 @entity1 , when @entity632 was added to @entity2592 , we observed 1 @entity204 during induction and 1 failure. Of the @entity1 achieving CR 8 were treated by periodic courses with high dose @entity2592 and 4 of them relapsed. The longest failure free duration was 11 months. Median survival duration of the 17 @entity1 is 5 months.
